Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where James Mountz is active.

Publication


Featured researches published by James Mountz.


NeuroImage | 2013

Classification of amyloid-positivity in controls: Comparison of visual read and quantitative approaches

Ann D. Cohen; Wenzhu Mowrey; Lisa A. Weissfeld; Howard J. Aizenstein; Eric McDade; James Mountz; Robert D. Nebes; Judith Saxton; Beth E. Snitz; Steven T. DeKosky; Jeff D. Williamson; Oscar L. Lopez; Julie C. Price; Chester A. Mathis; William E. Klunk

UNLABELLED An important research application of amyloid imaging with positron emission tomography (PET) is detection of the earliest evidence of fibrillar amyloid-beta (Aβ) deposition. Use of amyloid PET for this purpose, requires a reproducible method for defining a cutoff that separates individuals with no significant Aβ deposition from those in which Aβ deposition has begun. We previously reported the iterative outlier approach (IO) for the analysis of Pittsburgh Compound-B (PiB) PET data. Developments in amyloid imaging since the initial report of IO have led us to re-examine the generalizability of this method. IO was developed using full-dynamic atrophy-corrected PiB PET data obtained from a group of control subjects with a fairly distinct separation between PiB-positive [PiB(+)] and PiB-negative [PiB(-)] subjects. METHODS We tested the performance of IO using late-summed tissue ratio data with atrophy correction or with an automated template method without atrophy correction and tested the robustness of the method when applied to a cohort of older subjects in which separation between PiB(+) and PiB(-) subjects was not so distinct. RESULTS The IO method did not perform consistently across analyses and performed particularly poorly when separation was less clear. We found that a sparse k-means (SKM) cluster analysis approach performed significantly better; performing more consistently across methods and subject cohorts. We also compared SKM to a consensus visual read approach and found very good correspondence. CONCLUSION The visual read and SKM methods, applied together, may optimize the identification of early Aβ deposition. These methods have the potential to provide a standard approach to the detection of PiB-positivity that is generalizable across centers.


Society of Nuclear Medicine Annual Meeting Abstracts | 2009

Human dosimetry of the PET radioligand [C-11]flumazenil (FMZ)

Charles M. Laymon; Rajesh Narendran; Neale Scott Mason; Jonathon Carney; Brian J. Lopresti; James Mountz; Chester A. Mathis; Gordon Frankle


Archive | 2009

Human Biodistribution and Dosimetry of the D 2/3 Agonist 11 C-N-Propylnorapomorphine ( 11 C-NPA) Determined from PET

Charles M. Laymon; N. Scott Mason; W. Gordon Frankle; Jonathan Carney; Brian J. Lopresti; Maralee Y. Litschge; Chester A. Mathis; James Mountz; Rajesh Narendran


Tomography: A Journal for Imaging Research | 2016

[18F]ML-10 PET: Initial Experience in Glioblastoma Multiforme Therapy Response Assessment

Matthew J. Oborski; Charles M. Laymon; F. Lieberman; Yongxian Qian; Jan Drappatz; James Mountz


Society of Nuclear Medicine Annual Meeting Abstracts | 2014

A practical, time-efficient, cost-effective protocol for obtaining dynamic PET scan data in the routine clinical setting

Alexandria Zahner; Matthew J. Oborski; Michael Czachowski; Charles M. Laymon; Robert L. Ferris; James Mountz


Society of Nuclear Medicine Annual Meeting Abstracts | 2014

A clinically feasible protocol for measuring 18F-FDG tracer kinetics in SCCHN patients before and after therapy

Alexandria Zahner; Matthew J. Oborski; Charles M. Laymon; Robert L. Ferris; James Mountz


Archive | 2014

Variations of Dynamic Contrast-Enhanced Magnetic ResonanceImaginginEvaluation

Wei Huang; Xin Li; Yiyi Chen; Xia Li; Ming-Ching Chang; Matthew J. Oborski; Dariya I. Malyarenko; Mark Muzi; Guido H. Jajamovich; Andriy Fedorov; Alina Tudorica; Sandeep N. Gupta; Charles M. Laymon; Kenneth I. Marro; Hadrien Dyvorne; James V. Miller; Daniel P. Barbodiak; Thomas L. Chenevert; Thomas E. Yankeelov; James Mountz; Paul Kinahan; Ron Kikinis; Bachir Taouli; Fiona M. Fennessy; Jayashree Kalpathy-Cramer


Society of Nuclear Medicine Annual Meeting Abstracts | 2013

Early therapy response assessment of epidermal growth factor receptor specific monoclonal antibody treated head and neck squamous cell carcinoma

Farzin Imani; Robert L. Ferris; James Mountz


Society of Nuclear Medicine Annual Meeting Abstracts | 2012

Early therapy response assessment with FLT in glioblastoma multiforme

Farzin Imani; Charles M. Laymon; Frank S. Lieberman; Matthew J. Oborski; Fernando E. Boada; James Mountz


Society of Nuclear Medicine Annual Meeting Abstracts | 2012

Additional impact of the diagnostic CT component of SPECT/CT in the assessment of neuroendocrine tumors

Gonca Bural; Ashok Muthukrishnan; Charles M. Laymon; James Mountz

Collaboration


Dive into the James Mountz's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Erin Deeb

University of Pittsburgh

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Farzin Imani

Post Graduate Institute of Medical Education and Research

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge